HDACi are regarded as agents capable of reactivating apoptosis in tumor cells by affecting very different parts of the apoptosis cascade; for example, through increased expression of death receptors like tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cell surface receptors or by directly stimulating a death receptor pathway without altered receptor expression [26]. Here, CD177 is linked to neoplasm.